Botanix Pharmaceuticals receives strong results amid growing dermatitis rates

Botanix Pharmaceuticals ASX BOT BTX 1204 phase 1b trial results
Botanix Pharmaceuticals achieved treatment success using its cannabidiol-based BTX 1204 in 35% of its atopic dermatitis patients during its phase 1b clinical trial.

Dermatology company Botanix Pharmaceuticals (ASX: BOT) has published successful results from its phase 1b patient study looking into the safety profile of its cannabidiol-based BTX 1204 transdermal gel that aims to treat atopic dermatitis.

Atopic dermatitis (a severe form of eczema that appears as itchy inflammation of the skin) currently affects between 15-30 million people in the United States and around “10-15% of Australia’s population including 39% of all children,” according to the University of Melbourne.

Although Botanix’s published results

... read more at: